Related Experiment Video
Updated: May 13, 2025
07:43
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
18.8K
MRI based radiomics nomogram for predict recurrence of non functioning pituitary macroadenomas post surgery
Ji-Ping Zhao1, Xue-Jun Liu1, Hao-Zhi Lin2
1Department of Radiology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Scientific Reports
|April 14, 2025
Summary
A new combined model accurately predicts non-functioning pituitary macroadenoma (NFMA) recurrence within five years. This tool integrates clinical data and radiomics, guiding follow-up and adjuvant therapy for high-risk patients.
Area of Science:
- Endocrinology
- Radiology
- Oncology
Background:
- Non-functioning pituitary macroadenomas (NFMA) pose a risk of recurrence after surgery.
- Accurate prediction of recurrence is crucial for effective patient management and treatment planning.
Purpose of the Study:
- To develop and validate a comprehensive predictive model for five-year recurrence of NFMA.
- To integrate clinical data with radiomics features for enhanced prediction accuracy.
Main Methods:
- Retrospective analysis of 292 NFMA patients with an external validation set of 123 patients.
- Extraction of radiomic features from preoperative MRI (T1WI, T2WI, enhanced).
- Development of clinical, radiomics, and combined predictive models, evaluated using ROC, calibration curves, and DCA.
Main Results:
- The combined model demonstrated superior predictive performance in the external test set with an AUC of 0.863.
- Radiomics model (AUC 0.835) and clinical model (AUC 0.757) also showed significant predictive capabilities.
- The combined model exhibited high sensitivity (80%) and specificity (81.93%), with excellent calibration and clinical utility.
Conclusions:
- The combined clinical and radiomics model offers a more accurate prediction of NFMA recurrence.
- This predictive tool can optimize postoperative surveillance strategies.
- It facilitates timely initiation of adjuvant therapy for patients identified as high-risk for recurrence.
